- Home
- CUE vs PEPG Comparison
CUE vs PEPG Comparison
Compare CUE & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- PEPG
- Stock Information
- Founded
- CUE 2014
- PEPG 2018
- Country
- CUE United States
- PEPG United States
- Employees
- CUE N/A
- PEPG N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- PEPG Health Care
- Exchange
- CUE Nasdaq
- PEPG Nasdaq
- Market Cap
- CUE 48.0M
- PEPG 45.5M
- IPO Year
- CUE 2018
- PEPG 2022
- Fundamental
- Price
- CUE $0.74
- PEPG $1.25
- Analyst Decision
- CUE Strong Buy
- PEPG Buy
- Analyst Count
- CUE 3
- PEPG 3
- Target Price
- CUE $3.00
- PEPG $7.67
- AVG Volume (30 Days)
- CUE 323.3K
- PEPG 340.5K
- Earning Date
- CUE 08-13-2025
- PEPG 08-07-2025
- Dividend Yield
- CUE N/A
- PEPG N/A
- EPS Growth
- CUE N/A
- PEPG N/A
- EPS
- CUE N/A
- PEPG N/A
- Revenue
- CUE $7,991,000.00
- PEPG N/A
- Revenue This Year
- CUE N/A
- PEPG N/A
- Revenue Next Year
- CUE $23.84
- PEPG N/A
- P/E Ratio
- CUE N/A
- PEPG N/A
- Revenue Growth
- CUE 13.83
- PEPG N/A
- 52 Week Low
- CUE $0.45
- PEPG $0.88
- 52 Week High
- CUE $1.99
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- CUE 51.10
- PEPG 46.05
- Support Level
- CUE $0.65
- PEPG $1.07
- Resistance Level
- CUE $0.83
- PEPG $1.27
- Average True Range (ATR)
- CUE 0.07
- PEPG 0.10
- MACD
- CUE 0.01
- PEPG -0.00
- Stochastic Oscillator
- CUE 30.43
- PEPG 45.45
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.